AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20852881 — intervention group
Group type: COMPARATOR
Intervention: Room air (RA)
Number of subjects: 11
Study 20852881 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox (HX)
Number of subjects: 11
Study 18367379 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition with daily glutamine supplement of 0.35 g/kg
Number of subjects: 30
Study 18367379 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric‐isonitrogenous parenteral nutrition (Control)
Number of subjects: 30
Study 15886045 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic carpal tunnel syndrome (CTS) subjects
Number of subjects: 11
Study 15886045 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic subjects (control)
Number of subjects: 11
Study 12633918 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg buprenorphine tablets sublingually for 10 days
Number of subjects: 24
Study 11520747 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative 5-FU
Number of subjects: 68
Study 11520747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 9104860 — intervention group
Group type: COMPARATOR
Intervention: Euhydrated with an esophageal temperature (T(es)) of 38.1-38.3 degrees C (control)
Number of subjects: 15
Study 9104860 — intervention group
Group type: EXPERIMENTAL
Intervention: Euhydrated and hyperthermic (T(es) of 39.3 degrees C)
Number of subjects: 15
Study 9104860 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydrated and hyperthermic with skin temperature (T(sk)) of 34 degrees C
Number of subjects: 15
Study 9104860 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydrated with T(es) of 38.1 degrees C and T(sk) of 21 degrees C
Number of subjects: 15
Study 9104860 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition 4 followed by restored blood volume
Number of subjects: 15
Study 7926425 — intervention group
Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 25
Study 7926425 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 25
Study 7926425 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide and Insulin
Number of subjects: 25
Study 3440508 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 53
Study 3440508 — intervention group
Group type: COMPARATOR
Intervention: Alginate/antacid chewing tablets and metoclopramide
Number of subjects: 53
Study 2486782 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 days triphasic group (T-21)
Number of subjects: 100
Study 2486782 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 days triphasic group (T-28)
Number of subjects: 100
Study 2486782 — intervention group
Group type: COMPARATOR
Intervention: 28 days monophasic group (M-28)
Number of subjects: 100
Study 2486782 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall tolerance of triphasic preparation (LOGYNON)
Number of subjects: 100
Study 31868816 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing training load during a 10 repetition maximum (RM) test
Number of subjects: 29
Study 31868816 — intervention group
Group type: COMPARATOR
Intervention: Lower body exercises
Number of subjects: 29
Study 31868816 — intervention group
Group type: COMPARATOR
Intervention: Upper body exercises
Number of subjects: 29
Study 31868816 — intervention group
Group type: COMPARATOR
Intervention: Machine exercises
Number of subjects: 29
Study 31868816 — intervention group
Group type: COMPARATOR
Intervention: Free-weight exercises
Number of subjects: 29
Study 31952632 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylazine (0.20 mg kg‐1)
Number of subjects: 10
Study 31952632 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.005 mg kg‐1)
Number of subjects: 10
Study 31952632 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 10
Study 29199999 — intervention group
Group type: COMPARATOR
Intervention: Lavender group (n = 41)
Number of subjects: 123
Study 29199999 — intervention group
Group type: COMPARATOR
Intervention: Eucalyptus group (n = 41)
Number of subjects: 123
Study 29199999 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 41)
Number of subjects: 123
Study 28991096 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive rehabilitation intervention
Number of subjects: 0
Study 25091954 — intervention group
Group type: EXPERIMENTAL
Intervention: Brilliant blue G (BBG) under air infusion (group 1)
Number of subjects: 63
Study 25091954 — intervention group
Group type: COMPARATOR
Intervention: Brilliant blue G (BBG) injected into the vitreous cavity (group 2)
Number of subjects: 63
Study 23021155 — intervention group
Group type: EXPERIMENTAL
Intervention: Mustard (21 g)
Number of subjects: 22
Study 23021155 — intervention group
Group type: EXPERIMENTAL
Intervention: Horseradish (8.3 g)
Number of subjects: 22
Study 23021155 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no spices)
Number of subjects: 22
Study 23021155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (20 g)
Number of subjects: 22
Study 23021155 — intervention group
Group type: EXPERIMENTAL
Intervention: Black pepper (1.3 g)
Number of subjects: 22
Study 22036523 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyprinol(®) 200mg daily for 8 weeks
Number of subjects: 20
Study 22036523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19463379 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa antagonist
Number of subjects: 149
Study 19463379 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (no GP IIb/IIIa antagonist)
Number of subjects: 149
Study 16998289 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 98
Study 16998289 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 98
Study 15448307 — intervention group
Group type: EXPERIMENTAL
Intervention: Token opportunities (few opportunities)
Number of subjects: 0
Study 15448307 — intervention group
Group type: COMPARATOR
Intervention: Closed opportunities (no opportunities)
Number of subjects: 0
Study 15448307 — intervention group
Group type: COMPARATOR
Intervention: Open opportunities (equal opportunities)
Number of subjects: 0
Study 11332869 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐dihydroergocryptine (10 mg twice daily)
Number of subjects: 40
Study 11332869 — intervention group
Group type: COMPARATOR
Intervention: propranolol (40 mg twice daily)
Number of subjects: 40
Study 9522971 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ofloxacin administration by caregivers
Number of subjects: 91
Study 9522971 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 91
Study 7950209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordyceps sinensis for 7 days
Number of subjects: 21
Study 7950209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 3508553 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate 25 mg
Number of subjects: 12
Study 3508553 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate 50 mg
Number of subjects: 12
Study 3508553 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate 75 mg
Number of subjects: 12
Study 3508553 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate 100 mg
Number of subjects: 12
Study 30075813 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-feedback Intervention to promote Positive Parenting and Sensitive Discipline in Foster Care (VIPP-FC)
Number of subjects: 60
Study 30075813 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study 27067604 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic group (DG)
Number of subjects: 33
Study 27067604 — intervention group
Group type: EXPERIMENTAL
Intervention: Module group (MG)
Number of subjects: 33
Study 27067604 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 33
Study 23844867 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous-containing sodium fluoride dentifrice
Number of subjects: 27
Study 23844867 — intervention group
Group type: COMPARATOR
Intervention: Negative control dentifrice
Number of subjects: 27
Study 22947545 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) exercise, performed two days per week for 6 months
Number of subjects: 52
Study 22947545 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 52
Study 20884870 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin plus dipyridamole
Number of subjects: 5700
Study 18432480 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced fMRI design
Number of subjects: 0
Study 16151021 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary transplantation of CPCs
Number of subjects: 26
Study 12542565 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) with transdermal 17‐beta oestradiol and medroxyprogesterone acetate
Number of subjects: 118
Study 12542565 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment for CHD
Number of subjects: 118
Study 12542565 — intervention group
Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 118
Study 11505388 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cycles of the same chemotherapy after 6 cycles of induction chemotherapy
Number of subjects: 82
Study 11505388 — intervention group
Group type: COMPARATOR
Intervention: (sub)total lymph node irradiation after 6 cycles of induction chemotherapy
Number of subjects: 82
Study 9248317 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (long-acting beta 2-agonist)
Number of subjects: 110
Study 9248317 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Quality of Life Questionnaire (AQLQ)
Number of subjects: 110
Study 9248317 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with Asthma Quality of Life Questionnaire (LWAQ)
Number of subjects: 110
Study 9248317 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Form 36 (SF-36)
Number of subjects: 110
Study 9248317 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological General Well Being (PGWB)
Number of subjects: 110
Study 9248317 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic QOL instruments
Number of subjects: 110
Study 9248317 — intervention group
Group type: EXPERIMENTAL
Intervention: AQLQ vs LWAQ
Number of subjects: 110
Study 9248317 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 vs PGWB and LWAQ
Number of subjects: 110
Study 8256188 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime (2 grams every 12 hours)
Number of subjects: 149
Study 8256188 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin and mezlocillin (gentamicin 1.0 to 1.5 mg/kg every 8 hours; mezlocillin 3 to 4 grams every 4 to 6 hours)
Number of subjects: 149
Study 3321867 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 0
Study 3321867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31370128 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral prednisolone twice daily for four days
Number of subjects: 73
Study 31370128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 28882536 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin 75 mg/m2 on day 1 every 3 weeks
Number of subjects: 257
Study 28882536 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 675 mg/m2 on days 1 and 8 and docetaxel 75 mg/m2 on day 8 every 3 weeks
Number of subjects: 257
Study 25603432 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-drink and rest
Number of subjects: 30
Study 25603432 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-drink and exercise
Number of subjects: 30
Study 25603432 — intervention group
Group type: EXPERIMENTAL
Intervention: Water and exercise
Number of subjects: 30
Study 25603432 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-drink
Number of subjects: 30
Study 25603432 — intervention group
Group type: COMPARATOR
Intervention: Water and rest
Number of subjects: 30
Study 23991092 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic liver resection (Lap-Hx)
Number of subjects: 275
Study 23991092 — intervention group
Group type: COMPARATOR
Intervention: Open liver resection (Open-Hx)
Number of subjects: 275
Study 21194670 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative health coaching (2 to 28 sessions)
Number of subjects: 360
Study 21194670 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative health coaching
Number of subjects: 360
Study 19487177 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosamprenavir-ritonavir (FPV/r) with abacavir/lamivudine (ABC/3TC)
Number of subjects: 199
Study 19487177 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir-ritonavir (LPV/r) with abacavir/lamivudine (ABC/3TC)
Number of subjects: 199
Study 19487177 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosamprenavir-ritonavir (FPV/r)
Number of subjects: 199
Study 19487177 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir-ritonavir (LPV/r)
Number of subjects: 199
Study 17673814 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (60 mg/m2, every 3 weeks)
Number of subjects: 24
Study 17673814 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (60 mg/m2, every 3 weeks) + 5'DFUR (600 mg/body)
Number of subjects: 24
Study 15152060 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard medical therapy plus a single-chamber ICD
Number of subjects: 458
Study 15152060 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 458
Study 11332171 — intervention group
Group type: EXPERIMENTAL
Intervention: Beractant (100 mg kg-1) administered 2 hours after the first dose
Number of subjects: 57
Study 11332171 — intervention group
Group type: COMPARATOR
Intervention: Beractant (100 mg kg-1) administered 6 hours after the first dose
Number of subjects: 57
Study 9433436 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7995165 — intervention group
Group type: EXPERIMENTAL
Intervention: Defecography assessment by three observers
Number of subjects: 100
Study 7995165 — intervention group
Group type: EXPERIMENTAL
Intervention: Defecography assessment with clinical data provided
Number of subjects: 100
Study 7995165 — intervention group
Group type: EXPERIMENTAL
Intervention: Defecography assessment with residual volume in the lower rectum
Number of subjects: 100
Study 3143539 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral digoxin (0.125 mg three times daily up to 0.25 mg twice daily)
Number of subjects: 45
Study 3143539 — intervention group
Group type: COMPARATOR
Intervention: Oral digoxin (0.125 mg twice daily) and quinidine hydrogen sulphate (750‐1000 mg daily)
Number of subjects: 45
Study 3143539 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral digoxin (0.125 mg three times daily) and flecainide (200‐300 mg daily)
Number of subjects: 45
Study 31244349 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA)
Number of subjects: 112
Study 31244349 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection (SR)
Number of subjects: 112
Study 28442337 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-Factor Eating Questionnaire (TFEQ)
Number of subjects: 186
Study 28442337 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-Related Eating Questionnaire (WREQ)
Number of subjects: 186
Study 26488118 — intervention group
Group type: EXPERIMENTAL
Intervention: LE‐HMF
Number of subjects: 147
Study 26488118 — intervention group
Group type: COMPARATOR
Intervention: PI‐HMF
Number of subjects: 147
Study 23885033 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT lot A (ACWY-A) (68% O-acetylation)
Number of subjects: 1170
Study 23885033 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT lot B (ACWY-B) (92% O-acetylation)
Number of subjects: 1170
Study 23885033 — intervention group
Group type: COMPARATOR
Intervention: Men-PS (82% O-acetylation)
Number of subjects: 1170
Study 21806572 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model based on clinical characteristics and laboratory findings
Number of subjects: 703
Study 19531265 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-based psychologist delivered five session individualised cognitive behavioural intervention
Number of subjects: 560
Study 19531265 — intervention group
Group type: COMPARATOR
Intervention: Minimal contact self management
Number of subjects: 560
Study 16684279 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol
Number of subjects: 30
Study 16684279 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone aseponate (MPA)
Number of subjects: 30
Study 16684279 — intervention group
Group type: COMPARATOR
Intervention: Control (Normal skin)
Number of subjects: 30
Study 16684279 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol and MPA
Number of subjects: 30
Study 16279272 — intervention group
Group type: EXPERIMENTAL
Intervention: Most intensive, church‐based intervention arm
Number of subjects: 12400
Study 16279272 — intervention group
Group type: EXPERIMENTAL
Intervention: Other two intervention arms
Number of subjects: 12400
Study 16279272 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12400
Study 11368136 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal massage
Number of subjects: 684
Study 9224961 — intervention group
Group type: EXPERIMENTAL
Intervention: Delavirdine mesylate (400 mg every 8 hours for 30 days) + Rifabutin (300 mg once daily on days 16-30)
Number of subjects: 12
Study 9224961 — intervention group
Group type: COMPARATOR
Intervention: Delavirdine mesylate (400 mg every 8 hours for 30 days)
Number of subjects: 12
Study 7737957 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (antidepressant) for 12 weeks
Number of subjects: 200
Study 2183734 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced diuresis, chemotherapy, and plasmapheresis (group 2)
Number of subjects: 21
Study 2183734 — intervention group
Group type: COMPARATOR
Intervention: Forced diuresis and chemotherapy (group 1)
Number of subjects: 21
Study 2183734 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Number of subjects: 21
Study 457316 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical salicylic acid in hydrophilic ointment applied to skin with removed stratum corneum
Number of subjects: 0
Study 457316 — intervention group
Group type: COMPARATOR
Intervention: Topical salicylic acid in hydrophilic ointment applied to intact skin
Number of subjects: 0
Study 457316 — intervention group
Group type: COMPARATOR
Intervention: Topical salicylic acid in polyethylene glycol 400 vehicle
Number of subjects: 0
Study 31174172 — intervention group
Group type: EXPERIMENTAL
Intervention: Society of Critical Care Prioritization Model
Number of subjects: 257
Study 31174172 — intervention group
Group type: COMPARATOR
Intervention: Cancer specific flowchart
Number of subjects: 257
Study 28591240 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealant treatment (n = 28)
Number of subjects: 49
Study 28591240 — intervention group
Group type: COMPARATOR
Intervention: Restorative treatment (n = 26)
Number of subjects: 49
Study 25887235 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiComponent Exercise and theRApeutic lifeStyle (CERgAS) intervention program
Number of subjects: 164
Study 25887235 — intervention group
Group type: COMPARATOR
Intervention: General health education (Control)
Number of subjects: 164
Study 24843061 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up formula (FUF) with 25 mg DHA, 1.2 g PDX/GOS, and 8.7 mg yeast β‐glucan per serving, 3 servings per day for 28 weeks
Number of subjects: 100
Study 24843061 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up formula (FUF)
Number of subjects: 100
Study 24843061 — intervention group
Group type: COMPARATOR
Intervention: Control (unfortified, cow's milk‐based beverage)
Number of subjects: 100
Study 22773430 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebron™ 4 mg (Test)
Number of subjects: 24
Study 22773430 — intervention group
Group type: COMPARATOR
Intervention: Neo‐Sintrom™ 4 mg (Reference)
Number of subjects: 24
Study 20142065 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip Protector (HP) worn on the right or left side
Number of subjects: 797
Study 18052556 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) treatment
Number of subjects: 21
Study 18052556 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 21
Study 16269090 — intervention group
Group type: EXPERIMENTAL
Intervention: hBD-4 peptides from LPS-treated small airway epithelial cells (SAECs)
Number of subjects: 6
Study 16269090 — intervention group
Group type: EXPERIMENTAL
Intervention: hBD-4 peptides in patients with chronic LRTI
Number of subjects: 6
Study 16269090 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated SAECs)
Number of subjects: 6
Study 12122176 — intervention group
Group type: EXPERIMENTAL
Intervention: FULL (six days of bed rest)
Number of subjects: 107
Study 12122176 — intervention group
Group type: COMPARATOR
Intervention: NO (no bed rest)
Number of subjects: 107
Study 10098562 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-mode method
Number of subjects: 930
Study 10098562 — intervention group
Group type: COMPARATOR
Intervention: Telephone-mode sample
Number of subjects: 930
Study 10098562 — intervention group
Group type: COMPARATOR
Intervention: Second telephone-mode sample with enhanced locating procedures
Number of subjects: 930
Study 8683518 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage weight loss (%WL)
Number of subjects: 84
Study 8683518 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 84
Study 8683518 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-arm muscle circumference (MAMC)
Number of subjects: 84
Study 8683518 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of %WL, BMI, and MAMC
Number of subjects: 84
Study 8683518 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid retention
Number of subjects: 84
Study 8683518 — intervention group
Group type: EXPERIMENTAL
Intervention: All three measurements (%WL, BMI, MAMC)
Number of subjects: 84
Study 8683518 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment by dietitian
Number of subjects: 84
Study 1522190 — intervention group
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotrophin (HCG) 1500 IU i.m. on days 3, 6, and 9 after the initial trigger
Number of subjects: 121